ARTICLE | Company News
RiboGene other research news
October 14, 1996 7:00 AM UTC
RiboGene received a $650,000 Phase II SBIR from the National Cancer Institute to discover and develop small molecule drugs based on the activity of the cellular enzyme protein kinase RNA-activated (PK...